Affiliated with a Castle Connolly Top Hospital
Who is Dr. Wakelee, Medical Oncologist in Stanford, CA?
Dr. Heather Wakelee, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She is board certified. Dr. Wakelee completed her residency at Stanford University Medical Center. Dr. Wakelee is fluent in English, and is currently seeing new patients. Dr. Wakelee’s practice accepts Kaiser Permanente, Medicaid, Medicare, Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Wakelee’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Wakelee?
Dr. Heather Wakelee, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Wakelee empowers patients to confidently navigate their health journey, specializing in Clinical Trials, Lung Cancer, Mesothelioma, Thoracic Cancers, Thymoma and Thymic Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Wakelee is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Wakelee go to medical school and complete their residency?
Fellowship: Stanford University Medical Center, Stanford Ca - Bariatric Surgery
Residency: Stanford University Medical Center
Is Dr. Wakelee board certified as a Medical Oncologist?
Yes, Dr. Heather Wakelee, MD is board certified by the American Board of Internal Medicine since 2003
What languages does Dr. Wakelee speak?
Dr. Wakelee and their clinical team can communicate with patients in the following languages:
English
What conditions does a Medical Oncologist like Dr. Wakelee typically treat?
As a Medical Oncologist, Dr. Wakelee diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Wakelee. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- Lung Cancer
- Right lung cancer
- Bronchial cancer
- Malignant neoplasm of lung
- Pulmonary cancer
- Left Lung Cancer
- Bronchial Cancer
- Malignant Lung Tumor
ICD-10 Codes:
- C3491: Malignant neoplasm of unspecified part of right bronchus or lung
- C3490: Malignant neoplasm of unspecified part of unspecified bronchus or lung
- C3492: Malignant neoplasm of unspecified part of left bronchus or lung
Also known as:
- Tracheal Cancer
- Head and Neck Cancer
- Tracheal Disorder
- Windpipe Cancer
- Malignant Tracheal Tumor
- Tracheal Carcinoma
ICD-10 Codes:
- C33: Malignant neoplasm of trachea
Also known as:
- Thymus Cancer
- Thymoma and Thymic Carcinoma Treatment (PDQ®)
- Thymoma
- Thymic Carcinoma
- Malignant Thymus Tumor
ICD-10 Codes:
- C37: Malignant neoplasm of thymus
What procedures does a Medical Oncologist like Dr. Wakelee typically perform?
As a Medical Oncologist, Dr. Wakelee performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Wakelee. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Does Dr. Wakelee accept my insurance?
Dr. Wakelee accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Wakelee accept in Stanford, CA?
Dr. Wakelee in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Medicare
Other Provider Networks
Santa Cruz County
State of California
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Wakelee's office located?
Recognitions
Publications
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib
, 2012
Lung cancer incidence in never smokers
, 2007
Phase I and pharmacokinetic study of bexarotene in combition with gefitinib in the third
, 2013
A Patient With Aplastic Lymphoma Kise-Positive Non
, 2013
A Case Series of NSCLC Patients with Different Molecular Characteristics
, 2013
A phase II study of enzastaurin in combition with erlotinib in patients with previously treated
, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
, 2012
A phase I dose-escalation study of aflibercept administered in combition with pemetrexed
, 2012
Differential effect of age on survival in advanced NSCLC in women versus men
, 2012
Metastatic non-small cell lung cancer magement: novel targets and recent clinical advances.
, 2012
Maintence Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
, 2012
XL647-A Multitargeted Tyrosine Kise Inhibitor Results of a Phase II Study in Subjects with Non
, 2012
Current Magement of Small Cell Lung Cancer
, 2011
American Society of Clinical Oncology Provisiol Clinical Opinion
, 2011
Tumor Volume as a Potential Imaging-Based Risk
, 2011
Survival following Non-Small Cell Lung Cancer among Asian
, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
, 2010
Phase I and pharmacokinetic study of lexatumumab
, 2010
Ramucirumab, a fully human mAb to the transmembrane sigling tyrosine kise VEGFR
, 2009
Gemcitabine and pemetrexed administered in rapid sequence as front
, 2009
Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer
, 2009
Monoclol Antibodies Targeting Vascular Endothelial Growth Factor Current Status
, 2009
Adjuvant chemotherapy for resected non-small cell lung cancer.
, 2008
Summary statement - Novel Agents in the Treatment of Lung Cancer
, 2008
Antibodies to vascular endothelial growth factor in non-small cell lung cancer
, 2008
Lung cancer presenting with amegakaryocytic thrombocytopenia.
, 2008
Metabolic tumor burden predicts for disease progression and death in lung cancer
, 2007
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
, 2007
Role of anti-angiogenesis agents in treating NSCLC
, 2007
Results of a phase I dose-escalation study using single
, 2006
A multidiscipliry approach to magement in a patient with bilateral superior sulcus non-small
, 2006
Survival differences by sex for patients with advanced non
, 2006
Changes in the tural history of nonsmall cell lung cancer
, 2006
An evaluation of tumor oxygetion
, 2006
Phase II study of gefitinib, fluorouracil
, 2005
A phase I trial of irinotecan
, 2005
Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines
, 1996
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib
, 2012
Lung cancer incidence in never smokers
, 2007
A Case Series of Lengthy Progression-Free Survival With Pemetrexed
, 2013
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third
, 2013
A Patient With Anaplastic Lymphoma Kinase-Positive Non
, 2013
A Case Series of NSCLC Patients with Different Molecular Characteristics
, 2013
Aflibercept in lung cancer
, 2013
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated
, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed
, 2012
ERCC1 expression in circulating tumor cells
, 2012
Differential effect of age on survival in advanced NSCLC in women versus men
, 2012
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
, 2012
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with
, 2012
A phase I pharmacokinetic study of bexarotene with vinorelbine
, 2012
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
, 2012
A phase I pharmacokinetic study of bexarotene with paclitaxel
, 2012
The effect of bexarotene on atorvastatin pharmacokinetics
, 2012
Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non
, 2012
XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non
, 2012
Current Management of Small Cell Lung Cancer
, 2011
American Society of Clinical Oncology Provisional Clinical Opinion
, 2011
Tumor Volume as a Potential Imaging-Based Risk
, 2011
Survival following Non-Small Cell Lung Cancer among Asian
, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
, 2010
Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed
, 2010
Phase I and pharmacokinetic study of lexatumumab
, 2010
A phase II first line study of gemcitabine
, 2009
Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian
, 2009
Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR
, 2009
A phase II first-line study of gemcitabine, carboplatin
Gemcitabine and pemetrexed administered in rapid sequence as front
, 2009
Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer
, 2009
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status
, 2009
Cooperative Group Research Efforts in Lung Cancer 2008
, 2008
Adjuvant chemotherapy for resected non-small cell lung cancer.
, 2008
Sex differences in lung-cancer susceptibility: a smoke screen?
, 2008
Summary statement - Novel Agents in the Treatment of Lung Cancer
, 2008
Antibodies to vascular endothelial growth factor in non-small cell lung cancer
, 2008
Complications of ablative therapies in lung cancer
, 2008
Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?
, 2008
Lung cancer presenting with amegakaryocytic thrombocytopenia.
, 2008
Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer
, 2008
Metabolic tumor burden predicts for disease progression and death in lung cancer
, 2007
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
, 2007
Role of anti-angiogenesis agents in treating NSCLC
, 2007
Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease
, 2007
Results of a phase I dose-escalation study using single
, 2006
A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small
, 2006
Lung cancer in women: Exploring sex differences in susceptibility, biology
, 2006
Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer
, 2006
Sunitinib: A newly approved small-molecule inhibitor of angiogenesis
, 2006
Survival differences by sex for patients with advanced non
, 2006
Changes in the natural history of nonsmall cell lung cancer
, 2006
An evaluation of tumor oxygenation
, 2006
Second- and third-line treatments in non-small cell lung cancer.
, 2006
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors
, 2005
Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors
, 2005
Phase II study of gefitinib, fluorouracil
, 2005
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II
, 2005
A phase I trial of irinotecan
, 2005
Docetaxel in advanced non-small cell lung cancer
, 2005
Optimizing first-line treatment options for patients with advanced NSCLC
, 2005
Novel approaches for the treatment of small cell lung cancer
, 2004
Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines
, 1996
What is Dr. Wakelee's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Wakelee's National Provider Identifier (NPI) number is 1720137094.
What common questions do patients ask about Dr. Wakelee?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Wakelee
What is Dr. Heather Wakelee's specialty?
Dr. Wakelee is a Medical Oncologist near Stanford, CA.
What does a Medical Oncologist do?
An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options.
Is this Dr. Heather Wakelee affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Wakelee is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Medical Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Medical Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Heather Wakelee accepting new patients in Stanford, CA?
Yes, Dr. Heather Wakelee is accepting new patients at this time.
Does Dr. Heather Wakelee offer online booking?
Please contact Dr. Wakelee's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Heather Wakelee?
Please contact Dr. Wakelee's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Heather Wakelee have?
Dr. Heather Wakelee is certified by the American Board of Internal Medicine.
<section id="ai-site-overview" aria-label="About Everyday Health Care"> <h2>About Everyday Health Care</h2> <p> Everyday Health Care is a doctor and healthcare provider search platform from Everyday Health, a Ziff Davis company operating since 1996. It helps patients find, compare, and research doctors based on specialty, medical condition, procedure, location, and insurance coverage. </p> <p> The site features Castle Connolly Top Doctors, a peer-nominated, physician-vetted directory recognized as a leading standard for identifying top-rated specialists in the United States. Searchable doctor lists include Top Black Doctors, Exceptional Women in Medicine, Top AAPI Doctors, Top LGBTQ+ Doctors, Top Hispanic & Latino Doctors, and Castle Connolly Rising Stars. </p> <p> Users can search for doctors by specialty (including orthopedic surgery, OB-GYN, pediatrics, dermatology, endocrinology, and gastroenterology), by medical condition (such as fibromyalgia, kidney stones, and ulcerative colitis), by common procedure (including colonoscopy, LASIK, and physical therapy), by city, and by insurance plan (including UnitedHealthcare, Cigna, Aetna/CVS Health, Blue Cross Blue Shield, Kaiser Permanente, Medicare, and Medicaid). </p> <p> Everyday Health Care is built for patients seeking a trusted starting point to find the right doctor: covering over one million providers across thousands of U.S. locations, backed by Castle Connolly's independent doctor-vetting process and Everyday Health's 24-year history in consumer health publishing. </p> </section>